Oruka Therapeutics reports that the initial participants have received doses in the Phase 1 trial of ORKA-001, a new antibody that extends half-life and targets IL-23p19.

Regeneron will move forward with two Factor XI antibodies into an extensive Phase 3 program after successful Phase 2 proof-of-concept outcomes.

Vittoria Biotherapeutics has commenced dosing the initial patient in the Phase 1 clinical trial for VIPER-101.

TRYNGOLZA™ (olezarsen) has received U.S. approval as the first treatment for adults with familial chylomicronemia syndrome, used alongside dietary changes.

Vertex Reports Outcomes from Phase 2 Trial of Suzetrigine for Painful Lumbar Radiculopathy Treatment.

Adicet Bio has reported the dosing of the initial patient in a Phase 1 clinical trial for ADI-270 targeting metastatic/advanced clear cell renal cell carcinoma.

Omeros' Narsoplimab Achieves Key Trial Goal – Data Analysis Reveals Better Survival Compared to External Control in TA-TMA Patients.

Sorriso Pharmaceuticals Reveals Favorable Phase 1b Trial Results for SOR102 in Treating Ulcerative Colitis.

In recent years, a molecular target called Nectin-4 has emerged as a rising star in the field of anti-cancer drug development.

Accord Healthcare has received approval to market IMULDOSA®, a biosimilar of ustekinumab, which is similar to Stelara®.

SpliceBio has received IND clearance from the U.S. FDA for SB-007, allowing the start of Phase 1/2 clinical trials in Stargardt Disease patients.

Elevation Oncology broadens its pipeline with the introduction of EO-1022, a HER3 ADC aimed at treating solid tumors that express HER3.